Alzheimer's - Dementia, Author Interviews, Herpes Viruses / 08.01.2025
Hebrew University Study Highlights Interplay of Herpes Virus and Tau in Alzheimer’s Disease
MedicalResearch.com Interview with:
[caption id="attachment_65850" align="alignleft" width="150"]
Dr. Or Shemesh[/caption]
Dr. Or Shemesh PhD
The Harvey M. Krueger Family Center for
Center for Nanoscience and Nanotechnology
School of Pharmacy - Institute for Drug Research
The Hebrew University of Jerusalem
MedicalResearch.com: What is the background for this study?
Response: Our study investigated the connection between herpes simplex virus 1 (HSV-1) and Alzheimer's disease (AD) pathologies. We explored how HSV-1 proteins are present in the brains of individuals with AD and examined their interactions with tau, a key protein in AD pathology.
MedicalResearch.com: What are the main findings?
Response: The main finding is that tau, traditionally seen as detrimental, might initially act as a protective response to HSV-1 by reducing neuronal death through an antiviral innate immunity pathway called cGAS-STING . Over time, this (initially beneficial) antiviral response of tau can manifest as the well established tau toxicity in Alzheimer's disease.
Dr. Or Shemesh[/caption]
Dr. Or Shemesh PhD
The Harvey M. Krueger Family Center for
Center for Nanoscience and Nanotechnology
School of Pharmacy - Institute for Drug Research
The Hebrew University of Jerusalem
MedicalResearch.com: What is the background for this study?
Response: Our study investigated the connection between herpes simplex virus 1 (HSV-1) and Alzheimer's disease (AD) pathologies. We explored how HSV-1 proteins are present in the brains of individuals with AD and examined their interactions with tau, a key protein in AD pathology.
MedicalResearch.com: What are the main findings?
Response: The main finding is that tau, traditionally seen as detrimental, might initially act as a protective response to HSV-1 by reducing neuronal death through an antiviral innate immunity pathway called cGAS-STING . Over time, this (initially beneficial) antiviral response of tau can manifest as the well established tau toxicity in Alzheimer's disease.
John W. Ayers, PhD, MA
Altman Clinical Translational Research Institute
University of California
San Diego, La Jolla
MedicalResearch.com: What is the background for this study?
Response: Crisis pregnancy centers (CPCs) are frequently at the center of news
and policy debates, yet little data exists about where they operate or
what they actually do. To address this gap, we developed
Dr. Yu Mengge[/caption]
Dr Yu Mengge
Research Fellow, Cancer & Stem Cell Biology Signature Research Programme
Duke-NUS Medical School
MedicalResearch.com: What is the background for this study?
Response: The background of this study is rooted in the observation that certain genetic variations among East Asian populations, notably the BIM deletion polymorphism (BDP), impact treatment outcomes in chronic myeloid leukaemia (CML).
Patients with the BDP show resistance to conventional treatments, specifically tyrosine kinase inhibitors like imatinib. This resistance stems from the variant's role in promoting cancer cell survival, which leads to more aggressive disease progression.